Insud Pharma
Sandra Villaescusa has extensive experience in financial reporting and audit supervision, currently serving in a Global Reporting & BPC role at Insud Pharma since March 2021. Prior experience includes a position as Senior Consolidation & Global Reporting at Ferrovial from June 2011 to March 2021, and serving as Team Leader Audit Supervisor at PwC from January 2007 to May 2011. Earlier in their career, Sandra worked as Head Waitress at Mendigoikoa S.L. from March 2000 to September 2006. Their educational qualifications encompass a Master in Audit from the University of Deusto, a leadership program from Centro Internacional de Negocio, English language certification from St Giles International, a degree in Business Administration from the Universidad del País Vasco, and a Master in Financial Management and Controlling from IEBS.
This person is not in the org chart
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.